Pulmonary hypertension, characterized by elevated pressures in the pulmonary arteries leading to abnormalities in right ventricular function, may lead to competing demands between the pulmonary and systemic circulation during sepsis and septic shock. As a result, management of pulmonary hypertension in sepsis, including identifying the source of infection, maintaining hemodynamic stability and continuing or transitioning pulmonary hypertension-specific therapies can often be challenging. The goal of this review is to highlight factors to consider in the evaluation and management of patients with pulmonary hypertension and sepsis.
SimonneauGMontaniDCelermajerDS, et al.Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019 Jan;53(1):1801913. PMCID: PMC6351336.
2.
HumbertMKovacsGHoeperMM, et al.2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618-3731. PMID: 36017548.
3.
EvansLRhodesAAlhazzaniW, et al.Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Crit Care Med.2021 Nov;49(11):e1063-e1143.
4.
SingerMDeutschmanCSSeymourCW, et al.The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016 Feb 23;315(8):801-810. PMCID: PMC4968574.
5.
LeverAMackenzieI. Sepsis: Definition, epidemiology, and diagnosis. Br Med J.2007 Oct 27;335(7625):879-883.
6.
CecconiMEvansLLevyMRhodesA. Sepsis and septic shock. Lancet.2018 Jul;392(10141):75-87.
7.
KhalidNPatelPDAlghareebRHussainAMaheshwariMV. The effect of sepsis on myocardial function: A review of pathophysiology, diagnostic criteria, and treatment. Cureus. 2022 Jun;14(6):e26178. PMCID: PMC9306401.
Cubero SalazarIMLancasterACJaniVP, et al.Poor cardiac output reserve in pulmonary arterial hypertension is associated with right ventricular stiffness and impaired interventricular dependence. Eur Respir J. 2024 Jul;64(1):2400420. PMID: 38843915.
10.
ChanCMKlingerJR. The right ventricle in sepsis. Clin Chest Med. 2008 Dec;29(4):661-676, ix. PMID: 18954701.
11.
ChanCKlingerJR. Sepsis and pulmonary arterial hypertension in the ICU. Advances in Pulmonary Hypertension. 2015 Jan 1;13(4):188-196.
12.
WijeratneDTLajkoszKBroglySB, et al.Increasing incidence and prevalence of world health organization groups 1 to 4 pulmonary hypertension: A population-based cohort study in Ontario, Canada. Circ Cardiovasc Qual Outcomes. 2018 Feb;11(2):e003973. PMCID: PMC5819352.
13.
VasudevaRChallaATuckNPothuruSVindhyalM. Hospital outcomes for patients with pulmonary arterial hypertension in sepsis and septic shock. BMC Pulm Med. 2022 Oct 3;22(1):374. PMCID: PMC9528158.
14.
HeWZhangWAnYHuangLLuoH. Impact of pulmonary arterial hypertension on systemic inflammation, cardiac injury and hemodynamics in sepsis: A retrospective study from MIMIC-III. Am J Med Sci. 2022 Apr;363(4):311-321. PMID: 35038420.
15.
FlynnSChenHKerbelR, et al.Management and outcomes in pulmonary arterial hypertension patients with sepsis. BMC Pulm Med. 2024 Oct 28;24(1):538. PMCID: PMC11520816.
16.
VallabhajosyulaSGeskeJBKumarMKashyapRKashaniKJentzerJC. Doppler-defined pulmonary hypertension in sepsis and septic shock. J Crit Care.2019 Apr;50:201-206.
17.
AryalSKingCS. Critical care of patients with pulmonary arterial hypertension. Curr Opin Pulm Med.2020 Sep;26(5):414-421.
18.
HarderEMSmallAMFaresWH. Primary cardiac hospitalizations in pulmonary arterial hypertension: Trends and outcomes from 2001 to 2014. Respir Med. 2020 Jan;161:105850. PMID: 32056724.
19.
KittermanNPomsAMillerDPLombardiSFarberHWBarstRJ. Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: Insights from the REVEAL REGISTRY®. Mayo Clin Proc.2012 Sep;87(9):825-834.
20.
TartavoulleTM. Management of sepsis in patients with pulmonary arterial hypertension in the intensive care unit. Crit Care Nurs Clin North Am.2017 Mar;29(1):15-23.
21.
RudigerASingerM. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med. 2007 Jun;35(6):1599-1608. PMID: 17452940.
22.
GreerJ. Pathophysiology of cardiovascular dysfunction in sepsis. BJA Education. 2015 Dec;15(6):316-321.
23.
SanfilippoFCorredorCFletcherN, et al.Left ventricular systolic function evaluated by strain echocardiography and relationship with mortality in patients with severe sepsis or septic shock: A systematic review and meta-analysis. Crit Care. 2018 Aug 4;22(1):183. PMCID: PMC6091069.
24.
KerkhofPLMvan de VenPMYooBPeaceRAHeyndrickxGRHandlyN. Ejection fraction as related to basic components in the left and right ventricular volume domains. Int J Cardiol. 2018 Mar 15;255:105-110. PMID: 29425548.
25.
TurakhiaMPMcManusDDWhooleyMASchillerNB. Increase in end-systolic volume after exercise independently predicts mortality in patients with coronary heart disease: Data from the heart and soul study. Eur Heart J. 2009 Oct;30(20):2478-2484. PMCID: PMC2761597.
26.
LeemanM. The pulmonary circulation in acute lung injury: A review of some recent advances. Intensive Care Med. 1991;17(5):254-260. PMID: 1939868.
27.
AiharaMNakazawaTDobashiK, et al.A selective pulmonary thrombosis associated with sepsis-induced disseminated intravascular coagulation. Intern Med. 1997 Feb;36(2):97-101.
28.
RudolphAMYuanS. Response of the pulmonary vasculature to hypoxia and H+ ion concentration changes. J Clin Invest. 1966 Mar;45(3):399-411. PMCID: PMC292711.
29.
HoustonBABrittainELTedfordRJ. Right ventricular failure. Taichman DB, editor. N Engl J Med. 2023 Mar 23;388(12):1111-1125.
30.
HauserBBrachtHMatejovicMRadermacherPVenkateshB. Nitric oxide synthase inhibition in sepsis?Lessons Learned from Large-Animal Studies: Anesthesia & Analgesia. 2005 Aug;101(2):488-498.
31.
SatoR. Nasu M. A review of sepsis-induced cardiomyopathy. J Intensive Care. 2015 Dec;3(1):48.
32.
FlynnAChokkalingam ManiBMatherPJ. Sepsis-induced cardiomyopathy: A review of pathophysiologic mechanisms. Heart Fail Rev. 2010 Nov;15(6):605-611.
33.
KumarAThotaVDeeLOlsonJUretzEParrilloJE. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med. 1996 Mar 1;183(3):949-958. PMCID: PMC2192364.
34.
WongCMBansalGPavlickovaLMarcocciLSuzukiYJ. Reactive oxygen species and antioxidants in pulmonary hypertension. Antioxid Redox Signal. 2013 May 10;18(14):1789-1796. PMCID: PMC3619148.
35.
SchlüterKDKutscheHSHirschhäuserCSchreckenbergRSchulzR. Review on chamber-specific differences in right and left heart reactive oxygen Species handling. Front Physiol. 2018 Dec 17;9:1799. PMCID: PMC6304434.
36.
BansalMMehtaAMachanahalli BalakrishnaA, et al.Right ventricular dysfunction in sepsis: An updated narrative review. Shock. 2023 Jun;59(6):829-837.
37.
CimolaiMCAlvarezSBodeCBuggerH. Mitochondrial mechanisms in septic cardiomyopathy. Int J Mol Sci. 2015 Aug 3;16(8):17763-17778. PMCID: PMC4581220.
38.
CrouserED. Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome. Mitochondrion. 2004 Sep;4(5-6):729-741. PMID: 16120428.
39.
ChotaliaMAliMAldermanJEPatelJMParekhDBangashMN. Cardiovascular subphenotypes in patients with COVID-19 pneumonitis whose lungs are mechanically ventilated: A single-centre retrospective observational study. Anaesthesia. 2022 Jul;77(7):763-771. PMCID: PMC9314994.
40.
Fraile-GutiérrezVZapata-FenorLBlandino-OrtizAGuerrero-MierMOchagavia-CalvoA. Right ventricular dysfunction in the critically ill. Echocardiographic evaluation. Med Intensiva (Engl Ed). 2024 Sep;48(9):528-542. PMID: 39079775.
41.
HuangSVieillard-BaronAEvrardB, et al.Echocardiography phenotypes of right ventricular involvement in COVID-19 ARDS patients and ICU mortality: Post-hoc (exploratory) analysis of repeated data from the ECHO-COVID study. Intensive Care Med. 2023 Aug;49(8):946-956. PMID: 37436445.
42.
ChertoffJChisumMGarciaBLascanoJ. Lactate kinetics in sepsis and septic shock: a review of the literature and rationale for further research. J Intensive Care. 2015 Oct 6;3:39. PMCID: PMC4594907.
43.
MarshallCLindgrenLMarshallBE. Metabolic and respiratory hydrogen ion effects on hypoxic pulmonary vasoconstriction. J Appl Physiol Respir Environ Exerc Physiol. 1984 Aug;57(2):545-550. PMID: 6469821.
44.
MullinCJVentetuoloCE. Critical care management of the patient with pulmonary hypertension. Clin Chest Med. 2021 Mar;42(1):155-165. PMID: 33541609.
45.
JensenJUHeinLLundgrenB, et al.Survival study (PASS) group. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial. Crit Care Med. 2011 Sep;39(9):2048-2058. PMID: 21572328.
46.
LayiosNLambermontBCanivetJL, et al.Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Crit Care Med. 2012 Aug;40(8):2304-2309. PMID: 22809906.
47.
LewisRADurringtonCCondliffeRKielyDG. BNP/NT-proBNP in pulmonary arterial hypertension: Time for point-of-care testing?. Eur Respir Rev. 2020;29(156):200009. PMC9488846.
48.
PradhanNMMullinCPoorHD. Biomarkers and right ventricular dysfunction. Crit Care Clin. 2020;36(1):141-153. PMC9982435.
49.
MermelLAAllonMBouzaE, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1-45. PMC4039170.
50.
SeitlerSDimopoulosKErnstSPriceLC. Medical emergencies in pulmonary hypertension. Semin Respir Crit Care Med. 2023 Dec;44(6):777-796. PMID: 37595615.
51.
Coz YatacoAAguinaga MezaMBuchKPDisselkampMA. Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure. Heart Fail Rev. 2016 May;21(3):323-346. PMCID: PMC7102249.
52.
HoeperMMGrantonJ. Intensive care unit management of patients with severe pulmonary hypertension and right heart failure. Am J Respir Crit Care Med. 2011 Nov 15;184(10):1114-1124. PMID: 21700906.
53.
HoeperMMLeeSHVoswinckelR, et al.Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006 Dec 19;48(12):2546-2552. PMID: 17174196.
54.
HarveySHarrisonDASingerM, et al.Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-man): A randomised controlled trial. Lancet. 2005 Aug 6;366(9484):472-477. PMID: 16084255.
55.
EvansCEZhaoYY. Impact of thrombosis on pulmonary endothelial injury and repair following sepsis. Am J Physiol Lung Cell Mol Physiol. 2017 Apr 1;312(4):L441-L451. PMCID: PMC5407094.
56.
TschaikowskyKSägnerSLehnertNKaulMRitterJ. Endothelin in septic patients: Effects on cardiovascular and renal function and its relationship to proinflammatory cytokines. Crit Care Med. 2000 Jun;28(6):1854-1860. PMID: 10890632.
57.
VincentJLRhodesAPerelA, et al.Clinical review: Update on hemodynamic monitoring–a consensus of 16. Crit Care. 2011 Aug 18;15(4):229. PMCID: PMC3387592.
58.
GrinsteinJGomberg-MaitlandM. Management of pulmonary hypertension and right heart failure in the intensive care unit. Curr Hypertens Rep. 2015 May;17(5):32. PMID: 25833459.
59.
HollenbergSM. Vasoactive drugs in circulatory shock. Am J Respir Crit Care Med. 2011 Apr 1;183(7):847-855. PMID: 21097695.
60.
KerbaulFRondeletBMotteS, et al.Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit Care Med. 2004 Apr;32(4):1035-1040. PMID: 15071398.
61.
PriceLCWortSJFinneySJMarinoPSBrettSJ. Pulmonary vascular and right ventricular dysfunction in adult critical care: Current and emerging options for management: A systematic literature review. Crit Care. 2010;14(5):R169. PMCID: PMC3219266.
62.
RaffyOAzarianRBrenotF, et al.Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation. 1996 Feb 1;93(3):484-488. PMID: 8565165.
63.
LuiJKSanganiRAGillmeyerKR, et al. Hemodynamic response to oral vasodilator therapy in systemic sclerosis-related pulmonary hypertension. Cardiovasc Drugs Ther. 2024;38(3):651-656. PMCID: PMC10666735.
64.
RicciardiMJKnightBPMartinezFJRubenfireM. Inhaled nitric oxide in primary pulmonary hypertension: A safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol. 1998 Oct;32(4):1068-1073. PMID: 9768734.
65.
TonelliARAlnuaimatHMubarakK. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med. 2010 Apr;104(4):481-496. PMID: 20004088.
66.
SitbonOBrenotFDenjeanA, et al.Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med. 1995 Feb;151(2 Pt 1):384-389. PMID: 7842196.
67.
VallabhajosyulaSKumarMPandompatamG, et al.Prognostic impact of isolated right ventricular dysfunction in sepsis and septic shock: An 8-year historical cohort study. Ann Intensive Care. 2017 Sep 7;7(1):94. PMCID: PMC5589718.
68.
ZampieriFGBagshawSMSemlerMW. Fluid therapy for critically ill adults with sepsis: A review. JAMA. 2023 Jun 13;329(22):1967.
69.
PoorHDVentetuoloCE. Pulmonary hypertension in the intensive care unit. Prog Cardiovasc Dis. 2012 Sep-Oct;55(2):187-198. PMID: 23009915.
70.
DettmerMHolthausCVFullerBM. The impact of serial lactate monitoring on emergency department resuscitation interventions and clinical outcomes in severe sepsis and septic shock: An observational cohort study. Shock. 2015 Jan;43(1):55-61. PMCID: PMC4269567.
71.
HernándezGOspina-TascónGADamianiLP, et al.Effect of a resuscitation strategy targeting peripheral perfusion Status vs Serum lactate levels on 28-day mortality among patients with septic shock: The ANDROMEDA-SHOCK randomized clinical trial. JAMA. 2019 Feb 19;321(7):654-664. PMCID: PMC6439620.
72.
WeinbergerJKlompasMRheeC. What is the utility of measuring lactate levels in patients with sepsis and septic shock?Semin Respir Crit Care Med. 2021 Oct;42(5):650-661. PMID: 34544182.
73.
AdamoLNassifMENovakELaRueSJMannDL. Prevalence of lactic acidaemia in patients with advanced heart failure and depressed cardiac output. Eur J Heart Fail. 2017 Aug;19(8):1027-1033. PMCID: PMC5359085.
74.
UyarHYesilEKaradenizM, et al.The effect of high lactate level on mortality in acute heart failure patients with reduced ejection fraction without cardiogenic shock. Cardiovasc Toxicol. 2020 Aug;20(4):361-369. PMID: 32048133.
75.
Querejeta RocaGCampbellPClaggettBSolomonSDShahAM. Right atrial function in pulmonary arterial hypertension. Circ Cardiovasc Imaging. 2015 Nov;8(11):e003521. discussion e003521. PMCID: PMC4629509.
76.
WesselsJNvan WezenbeekJde RoverJ, et al.Right atrial adaptation to precapillary pulmonary hypertension: Pressure-volume, cardiomyocyte, and histological analysis. J Am Coll Cardiol. 2023 Aug 22;82(8):704-717. PMID: 37587582.
77.
AsllanajBBengeEBaeJMcWhorterY. Fluid management in septic patients with pulmonary hypertension, review of the literature. Front Cardiovasc Med. 2023 Mar 2;10:1096871. PMCID: PMC10017881.
78.
BouzatPWaltherGRuppTLevyPVergèsS. Inferior vena cava diameter may be misleading in detecting central venous pressure elevation induced by acute pulmonary hypertension. Am J Respir Crit Care Med. 2014 Jul 15;190(2):233-235. PMID: 25025357.
79.
JangAYShinMS. Echocardiographic screening methods for pulmonary hypertension: A practical review. J Cardiovasc Imaging. 2020 Jan;28(1):1-9. PMCID: PMC6992915.
80.
KawataTDaimonMNakanishiK, et al.Factors influencing inferior vena cava diameter and its respiratory variation: Simultaneous comparison with hemodynamic data. J Cardiol. 2022 May;79(5):642-647. PMID: 34895983.
81.
EgbeACConnollyHMPellikkaPAAndersonJHMirandaWR. Role of Inferior vena Cava dynamics for estimating right atrial pressure in congenital heart disease. Circ Cardiovasc Imaging. 2022 Sep;15(9):e014308. PMCID: PMC9504388.
82.
RistowBNaBAliSWhooleyMASchillerNB. Left ventricular outflow tract and pulmonary artery stroke distances independently predict heart failure hospitalization and mortality: The heart and soul study. J Am Soc Echocardiogr.2011 May;24(5):565-572.
83.
LamiaBOchagaviaAMonnetXChemlaDRichardCTeboulJL. Echocardiographic prediction of volume responsiveness in critically ill patients with spontaneously breathing activity. Intensive Care Med. 2007 Jul;33(7):1125-1132. PMID: 17508199.
84.
MaizelJAirapetianNLorneETribouilloyCMassyZSlamaM. Diagnosis of central hypovolemia by using passive leg raising. Intensive Care Med. 2007 Jul;33(7):1133-1138. PMID: 17508202.
85.
StrichJRHeilELMasurH. Considerations for empiric antimicrobial therapy in sepsis and septic shock in an era of antimicrobial resistance. J Infect Dis. 2020 Jul 21;222(Suppl 2):S119-S131. PMCID: PMC7372215.
86.
HanZLiangSYMarschallJ. Current strategies for the prevention and management of central line-associated bloodstream infections. Infect Drug Resist. 2010;3:147-163. PMCID: PMC3108742.
87.
LuiJKMesfinNTugalDKlingsESGovenderPBermanJS. Critical care of patients with cardiopulmonary complications of sarcoidosis. J Intensive Care Med. 2022 Apr;37(4):441-458. PMID: 33611981.
88.
GuenezanJDrugeonBMarjanovicNMimozO. Treatment of central line-associated bloodstream infections. Crit Care. 2018 Nov 16;22(1):303. PMCID: PMC6240203.
89.
JentzerJCMathierMA. Pulmonary hypertension in the intensive care unit. J Intensive Care Med. 2016 Jul;31(6):369-385.
90.
HoeperMMBenzaRLCorrisP, et al.Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J. 2019 Jan;53(1):1801906. PMCID: PMC6351385.
91.
KwakYLLeeCSParkYHHongYW. The effect of phenylephrine and norepinephrine in patients with chronic pulmonary hypertension*. Anaesthesia. 2002 Jan;57(1):9-14. PMID: 11843735.
92.
ZamanianRTHaddadFDoyleRLWeinackerAB. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med. 2007 Sep;35(9):2037-2050. PMID: 17855818.
93.
RichSGubinSHartK. The effects of phenylephrine on right ventricular performance in patients with pulmonary hypertension. Chest. 1990 Nov;98(5):1102-1106. PMID: 2225953.
94.
DallaKBech-HanssenORickstenS. Impact of norepinephrine on right ventricular afterload and function in septic shock—a strain echocardiography study. Acta Anaesthesiol Scand. 2019 Nov;63(10):1337-1345.
95.
Le TulzoYSeguinPGacouinA, et al.Effects of epinephrine on right ventricular function in patients with severe septic shock and right ventricular failure: A preliminary descriptive study. Intensive Care Med. 1997 Jun;23(6):664-670. PMID: 9255647.
96.
MizotaTFujiwaraKHamadaMMatsukawaSSegawaH. Effect of arginine vasopressin on systemic and pulmonary arterial pressure in a patient with pulmonary hypertension secondary to pulmonary emphysema: A case report. JA Clin Rep. 2017;3(1):1. PMCID: PMC5813718.
97.
TayamaEUedaTShojimaT, et al.Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. Interact Cardiovasc Thorac Surg. 2007 Dec;6(6):715-719. PMID: 17704123.
98.
YiminHXiaoyuLYupingHWeiyanLNingL. The effect of vasopressin on the hemodynamics in CABG patients. J Cardiothorac Surg. 2013 Mar 16;8:49. PMCID: PMC3610232.
99.
RosenzweigEBBrodieDAbramsDCAgerstrandCLBacchettaM. Extracorporeal membrane oxygenation as a novel bridging strategy for acute right heart failure in group 1 pulmonary arterial hypertension. ASAIO J. 2014;60(1):129-133. PMID: 24299971.
100.
ArabiYMMcClaveSA. Enteral nutrition should not be given to patients on vasopressor agents. Crit Care Med. 2020;48(1):119-121. PMID: 30134303.
101.
WischmeyerPE. Enteral nutrition can be given to patients on vasopressors. Crit Care Med. 2020 Jan;48(1):122-125. PMCID: PMC8101503.
ConnellyDDelahantyJPatelS, et al.Inhaled epoprostenol for management of acute respiratory failure and pulmonary vascular disease. Pulm Pharmacol Ther. 2025 Sep:90:102374. PMCID: PMC12261948.
104.
LiJAugustynovichAEGurnaniPKFinkJB. In-vitro and in-vivo comparisons of high versus low concentrations of inhaled epoprostenol to adult intubated patients. Respir Res. 2021 Aug 21;22(1):231. PMCID: PMC8379597.
105.
ParkerDKShenSZhengJ, et al.Inhaled treprostinil drug delivery during mechanical ventilation and spontaneous breathing using two different nebulizers. Pediatr Crit Care Med. 2017 Jun;18(6):e253-e260. PMCID: PMC5478389.
106.
PatelRBSmaldoneGCCucciaADStrachanP. In vitro delivery of aerosolized treprostinil via modern mechanical ventilation. J Aerosol Med Pulm Drug Deliv. 2013 Aug;26(4):200-207. PMID: 23668545.
107.
FosterEMSullingerDCoonsJC. Management considerations for pulmonary arterial hypertension pharmacotherapy in the intensive care unit. Pharmacy. 2023 Sep 13;11(5):145.
108.
HonKECheungKSiuK, et al.Oral sildenafil for treatment of severe pulmonary hypertension in an infant. Biol Neonate. 2005;88(2):109-112. PMID: 15870496.
109.
MuzevichKMChohanHGrinnanDC. Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness. Crit Care. 2014 Oct 7;18(5):523. PMCID: PMC4331447.
110.
YoussefDEHandlerSSRichardsSM, et al.Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A north American experience. Front Pediatr. 2023 Jan 26;11:1055131. PMCID: PMC9909267.
111.
FenderRAHasselmanTEWangYHarthanAA. Evaluation of the tolerability of intermittent intravenous sildenafil in pediatric patients with pulmonary hypertension. J Pediatr Pharmacol Ther. 2016;21(5):419-425. PMCID: PMC5103649.
112.
ChilesJWVijaykumarKDarbyA, et al.Letter to the editor: “use of inhaled epoprostenol with high flow nasal oxygen in non-intubated patients with severe COVID-19”. J Crit Care. 2022 Jun;69:153989. PMCID: PMC8863404.
113.
LiJHarnoisLJMarkosB, et al.Epoprostenol delivered via high flow nasal cannula for ICU subjects with severe hypoxemia comorbid with pulmonary hypertension or right heart dysfunction. Pharmaceutics. 2019 Jun 14;11(6):281. PMCID: PMC6631264.
114.
KloseHChinKMEwertR, et al.Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: Safety, tolerability, and pharmacokinetic results from an open-label, phase III study. Respir Res. 2021 Feb 3;22(1):34. PMCID: PMC7856757.
115.
PanIZCareyJRJacobsJA, et al.Transitioning between prostanoid therapies in pulmonary arterial hypertension. Front Med (Lausanne). 2020 Mar 31;7:81. PMCID: PMC7137736.
116.
RadosevichJJDeChristopherAIrandostMFannJFeldmanJ. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension. Am J Health Syst Pharm. 2020 Jul 23;77(15):1208-1212. PMID: 32620953.
117.
HoeperMMBadeschDBGhofraniHA, et al.Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023 Apr 20;388(16):1478-1490.
118.
MirandaACCornelioCKTranBACFernandezJ. Sotatercept: A first-in-class activin signaling inhibitor for pulmonary arterial hypertension. J Pharm Technol. 2025;41(3):134-143. PMCID: PMC11847314.
119.
ErshedMda SilvaABNFelix de Farias Dos SantosACHeoDCavalcanteDVSAljazeeriJ. Efficacy and safety of sotatercept in pulmonary arterial hypertension: A meta-analysis of randomized controlled trials. Expert Rev Respir Med. 2025 Jul 6:1-9. PMID: 40611681.
120.
ElshabourySMAndersonJR. Ambrisentan for the treatment of pulmonary arterial hypertension: Improving outcomes. Patient Prefer Adherence. 2013 May 8;7:401-409. PMCID: PMC3652514.
121.
KaufmannPOkuboKBrudererS, et al.Pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag. Am J Cardiovasc Drugs. 2015 Jun;15(3):195-203. PMCID: PMC4452035.
122.
KholdaniCAFaresWHTrowTK. Macitentan for the treatment of pulmonary arterial hypertension. Vasc Health Risk Manag. 2014 Nov 25;10:665-673. PMCID: PMC4251661.
123.
NarechaniaSTorbicHTonelliAR. Treatment discontinuation or interruption in pulmonary arterial hypertension. J Cardiovasc Pharmacol Ther. 2020 Mar;25(2):131-141.
124.
TorbicH. Management of pulmonary arterial hypertension in the ICU. J Pharm Pract. 2019 Jun;32(3):303-313. PMID: 30909801.
125.
DeFilippisEMTopkaraVKKirtaneAJTakedaKNakaYGaranAR. Mechanical circulatory support for right ventricular failure. Card Fail Rev. 2022 Apr 21;8:e14. PMCID: PMC9062706.
126.
GrantCRichardsJBFrakesMCohenJWilcoxSR. ECMO And right ventricular failure: Review of the literature. J Intensive Care Med. 2021 Mar;36(3):352-360. PMID: 31964208.
